XSHE
002612
Market cap1.11bUSD
Sep 30, Last price
16.72CNY
Name
Lancy Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lancy Co., Ltd. is primarily engaged in the design, manufacturing, and marketing of branded women's apparel. The company's fashion portfolio includes various labels such as LANCYFROM25, LIMEFLARE, liaalancy, MOJOS.PHINE, JIGOTT, FABIANAFILIPPI, and m.tsubomi. Beyond its core fashion operations, Lancy has diversified into the medical aesthetics and healthcare sector. This includes overseeing and running medical institutions under the Milan Boyu brand, providing specialized laser and minimally invasive cosmetic treatments through its medical youth brand, and managing comprehensive aesthetic centers. These Gaoyisheng Medical Beauty centers offer a broad spectrum of services, ranging from cosmetic surgery and dermatological care to traditional Chinese aesthetic medicine, cosmetic dentistry, and micro-plastic procedures. Additionally, the company supplies clothing for infants and children, featuring popular brands like Agabang, ETTOI, Putto, Designskin, and DearBaby. Lancy distributes its wide array of products through both its physical retail stores and various online channels. The company was founded in 2000 and is headquartered in Beijing, China.
Related entities
Subsidiaries
朗姿时尚(香港)有限公司
Key people
Licheng Hou
Chief Financial Officer · since 2024
Jinhua Shen
General Manager, Director · since 2010
Jing Chang
Deputy General Manager · since 2024
Guoxiang Wang
Deputy General Manager · since 2012
Deputy General Manager, Secretary of the Board · since 2012
Dongri Shen
Chairman of the Board · since 2010
Heng Zhao
Director · since 2021
Qing Wang
Independent Director · since 2016
Youqian Zhu
Independent Director · since 2019
Headquarters & legal address
北京市顺义区马坡镇白马路63号
顺义区, BJ 100000
CN
顺义区, BJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||